Supplementary figure 6 from Nrf2 Hyperactivation as a Driver of Radiotherapy Resistance and Suppressed Antitumor Immunity in Head and Neck Squamous Cell Carcinoma | Synapse
October 2, 2025Open Access
Supplementary figure 6 from Nrf2 Hyperactivation as a Driver of Radiotherapy Resistance and Suppressed Antitumor Immunity in Head and Neck Squamous Cell Carcinoma
Key Points
Nrf2 hyperactivation contributes to resistance against radiotherapy in squamous cell carcinoma.
Fractionated radiation therapy affects tumor growth mediated by keap1, pointing to altered immunity.
Research utilized experimental models to investigate the interplay between radiotherapy and nrf2 signaling.
Findings indicate a need for new strategies to enhance antitumor immunity in radiotherapy.
Abstract
Keap1 tumor growth influenced by fractionated radiation therapy